Literature DB >> 8788508

Alterations in responses to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium.

K R Bonson1, D L Murphy.   

Abstract

This study sought to investigate possible interactions between antidepressant agents and lysergic acid diethylamide (LSD) in humans through the use of retrospective questionnaires. Ten subjects were identified who used LSD during chronic (3 weeks or longer) periods of antidepressant administration. These subjects were asked to describe the phenomenological effects of self-administered hallucinogens prior to and during antidepressant treatment; a structured, standardized questionnaire was used to evaluate LSD experiences. Chronic tricyclic antidepressant administration was associated with subjective increases in physical, hallucinatory and psychological responses to LSD. Similarly, subjects receiving lithium chronically also reported increases in their responses to LSD. In contrast, subjects who had been chronically taking an monoamine oxidase (MAO) inhibitor reported subjective decreases in the effects of LSD. This is similar to a previous report by our group of a decreased response to LSD in individuals who were chronically taking serotonin-selective antidepressants. These altered responses to LSD most likely involve differential changes in central serotonin and dopamine receptor systems and are consistent with other recent data suggesting that the clinical efficacy of different classes of antidepressants may not necessarily rely on a common mechanism of action in the brain.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8788508     DOI: 10.1016/0166-4328(96)00102-7

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  9 in total

Review 1.  Human hallucinogen research: guidelines for safety.

Authors:  Mw Johnson; Wa Richards; Rr Griffiths
Journal:  J Psychopharmacol       Date:  2008-07-01       Impact factor: 4.153

Review 2.  The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future.

Authors:  Robin L Carhart-Harris; Guy M Goodwin
Journal:  Neuropsychopharmacology       Date:  2017-04-26       Impact factor: 7.853

3.  Serotonergic/glutamatergic interactions: potentiation of phencyclidine-induced stimulus control by citalopram.

Authors:  J C Winter; J R Eckler; K C Rice; R A Rabin
Journal:  Pharmacol Biochem Behav       Date:  2005-07       Impact factor: 3.533

Review 4.  Assessing the risk-benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research.

Authors:  David Bender; David J Hellerstein
Journal:  Psychopharmacology (Berl)       Date:  2022-01-13       Impact factor: 4.530

Review 5.  The promises and perils of psychedelic pharmacology for psychiatry.

Authors:  Tristan D McClure-Begley; Bryan L Roth
Journal:  Nat Rev Drug Discov       Date:  2022-03-17       Impact factor: 84.694

Review 6.  Predicting Reactions to Psychedelic Drugs: A Systematic Review of States and Traits Related to Acute Drug Effects.

Authors:  Jacob S Aday; Alan K Davis; Cayla M Mitzkovitz; Emily K Bloesch; Christopher C Davoli
Journal:  ACS Pharmacol Transl Sci       Date:  2021-03-05

7.  Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects.

Authors:  Anna M Becker; Friederike Holze; Tanja Grandinetti; Aaron Klaiber; Vanja E Toedtli; Karolina E Kolaczynska; Urs Duthaler; Nimmy Varghese; Anne Eckert; Edna Grünblatt; Matthias E Liechti
Journal:  Clin Pharmacol Ther       Date:  2021-11-22       Impact factor: 6.903

Review 8.  Serotonin and brain function: a tale of two receptors.

Authors:  R L Carhart-Harris; D J Nutt
Journal:  J Psychopharmacol       Date:  2017-08-31       Impact factor: 4.153

Review 9.  Serotonin toxicity of serotonergic psychedelics.

Authors:  Benjamin Malcolm; Kelan Thomas
Journal:  Psychopharmacology (Berl)       Date:  2021-07-12       Impact factor: 4.530

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.